Details for Patent: 11,007,167

Which drugs does patent 11,007,167 protect, and when does it expire?

Patent 11,007,167 protects TECFIDERA and is included in one NDA.

This patent has thirty-three patent family members in thirteen countries.

Summary for Patent: 11,007,167

Title:	Methods of treating multiple sclerosis
Abstract:	Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.
Inventor(s):	Novas; Mark (Lexington, MA), Zhang; Rui (Ray) (Sharon, MA)
Assignee:	Biogen MA Inc. (Cambridge, MA)
Application Number:	17/071,740
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 11,007,167

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Biogen Inc	TECFIDERA	dimethyl fumarate	CAPSULE, DELAYED RELEASE;ORAL	204063-001	Mar 27, 2013	AB	RX	Yes	No						METHOD OF TREATING MULTIPLE SCLEROSIS
Biogen Inc	TECFIDERA	dimethyl fumarate	CAPSULE, DELAYED RELEASE;ORAL	204063-002	Mar 27, 2013	AB	RX	Yes	Yes						METHOD OF TREATING MULTIPLE SCLEROSIS

International Family Members for US Patent 11,007,167

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2015350213
Australia	2020239734
Australia	2021269298
Canada	2967619
China	107106530
China	113368091
China	113368092